

LIGAND PHARMACEUTICALS INC
Form 4
February 14, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Sharp John P

2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [LGND]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2014

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
VP Finance and CFO

11119 NORTH TORREY PINES ROAD, SUITE 200

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

LA JOLLA, CA 92037

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2014		M		1,166	A	\$ 21 18,833
Common Stock	02/12/2014		S		1,166	D	\$ 74.27 17,667
Common Stock	02/12/2014		M		16,666	A	\$ 16.14 34,333
Common Stock	02/12/2014		S		16,666	D	\$ 74.27 17,667
Common Stock	02/12/2014		M		1,000	A	\$ 16.14 18,667

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

Common Stock	02/12/2014	S	1,000	D	\$ 74.27	17,667	D
Common Stock	02/12/2014	M	8,333	A	\$ 40.86	26,000	D
Common Stock	02/12/2014	S	8,333	D	\$ 75.73	17,667	D
Common Stock	02/12/2014	M	7,321	A	\$ 21	24,988	D
Common Stock	02/12/2014	S	7,321	D	\$ 74.27	17,667	D
Common Stock	02/12/2014	M	6,012	A	\$ 21	23,679	D
Common Stock	02/12/2014	S	6,012	D	\$ 75.73	17,667	D
Common Stock	02/12/2014	M	6,086	A	\$ 10.05	23,753	D
Common Stock	02/12/2014	S	6,086	D	\$ 74.27	17,667	D
Common Stock	02/12/2014	M	10,789	A	\$ 10.05	28,456	D
Common Stock	02/12/2014	S	10,789	D	\$ 75.73	17,667	D
Common Stock	02/12/2014	M	2,879	A	\$ 14.47	20,546	D
Common Stock	02/12/2014	S	2,879	D	\$ 75.73	17,667	D
Common Stock	02/12/2014	M	14,622	A	\$ 14.47	32,289	D
Common Stock	02/12/2014	S	14,622	D	\$ 74.27	17,667	D
Common Stock	02/12/2014	M	4,584	A	\$ 21.92	22,251	D
Common Stock	02/12/2014	S	4,584	D	\$ 74.27	17,667	D
Common Stock	02/12/2014	M	7,495	A	\$ 9.96	25,162	D
Common Stock	02/12/2014	S	7,495	D	\$ 74.27	17,667	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not

SEC 1474
(9-02)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares
					V	(A) (D)	Date Exercisable	Expiration Date		
Incentive Stock Option (right to buy)	\$ 10.05	02/12/2014	02/12/2014	M		10,789	(1)	02/17/2021	Common Stock	10,789
Incentive Stock Option (right to buy)	\$ 14.47	02/12/2014	02/12/2014	M		2,879	(2)	02/09/2022	Common Stock	2,879
Incentive Stock Option (right to buy)	\$ 16.14	02/12/2014	02/12/2014	M		16,666	(3)	02/15/2019	Common Stock	16,666
Incentive Stock Option (right to buy)	\$ 21	02/12/2014	02/12/2014	M		7,321	(4)	02/23/2018	Common Stock	7,321
Incentive Stock Option (right to buy)	\$ 21	02/12/2014	02/12/2014	M		6,012	(4)	02/23/2018	Common Stock	6,012
Incentive Stock Option (right to buy)	\$ 40.86	02/12/2014	02/12/2014	M		8,333	(5)	04/30/2017	Common Stock	8,333
Non-Qualified Stock Option (right to buy)	\$ 9.96	02/12/2014	02/12/2014	M		7,495	(6)	02/15/2020	Common Stock	7,495
Non-Qualified Stock Option (right to buy)	\$ 10.05	02/12/2014	02/12/2014	M		6,086	(1)	02/21/2021	Common Stock	6,086
Non-Qualified Stock Option (right to buy)	\$ 14.47	02/12/2014	02/12/2014	M		14,622	(2)	02/09/2022	Common Stock	14,622
Non-Qualified Stock Option	\$ 16.14	02/12/2014	02/12/2014	M		1,000	(7)	02/15/2019	Common Stock	1,000

(right to buy)

Non-Qualified Stock Option (right to buy)	\$ 21	02/12/2014	02/12/2014	M	1,166	<u>(4)</u>	02/23/2018	Common Stock	1,1
---	-------	------------	------------	---	-------	------------	------------	-----------------	-----

Non-Qualified Stock Option (right to buy)	\$ 21.92	02/12/2014	02/12/2014	M	4,584	<u>(8)</u>	02/15/2023	Common Stock	4,5
---	----------	------------	------------	---	-------	------------	------------	-----------------	-----

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sharp John P 11119 NORTH TORREY PINES ROAD, SUITE 200 LA JOLLA, CA 92037			VP Finance and CFO	

Signatures

John P. Sharp 02/14/2014

 Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11.
- (2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/09/12.
- (3) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/15/09.
- (4) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 2/23/08.
- (5) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 4/30/07.
- (6) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/10.
- (7) Grant to reporting person of options are immediately exercisable. The date of grant is 02/15/09.
- (8) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.